Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.68 |
| ▸ | DRD1 | P21728 | 2/20 | 0.68 |
| ▸ | HTR2A | P28223 | 2/20 | 0.68 |
| ▸ | HTR2C | P28335 | 2/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.68 |
| ▸ | HRH1 | P35367 | 2/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.68 |
| ▸ | DRD3 | P35462 | 2/20 | 0.68 |
| ▸ | HTR2B | P41595 | 2/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080473 | 0.87 | DRD2 (0.79) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL8022151 | 0.86 | DRD2 (0.80) | DRD2LMNACHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL4187406 | 0.86 | DRD2 (0.67) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL144624 | 0.82 | DRD2 (0.74) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL14359158 | 0.82 | HTR1A (0.65) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL2370828 | 0.82 | DRD2 (0.65) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL14359747 | 0.82 | DRD2 (0.65) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL14359523 | 0.82 | HTR1A (0.65) | DRD2LMNACHRM2HTR1AADRA2A | |
| Quetiapine SCHEMBL4283801 | 0.81 | DRD2 (1.00) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL14359442 | 0.81 | DRD2 (0.64) | DRD2LMNACHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252151-B1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE AND INTERMEDIATES THEREFOR | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2004-03-17 | — | — | EP | claimed |
| EP-1252151-A1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE AND INTERMEDIATES THEREFOR | EGIS GYOGYSZERGYAR RT. (HU) | 2002-10-30 | — | — | EP | claimed |
| WO-2001055125-A1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE AND INTERMEDIATES THEREFOR | EGIS Gyógyszergyár Rt. (HU) | 2001-08-02 | — | — | WO | claimed |
| EP-1781646-B1 | PROCESS FOR THE PREPARATION OF 11-(4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL)DIBENZO[b,f][1,4]THIAZEPINE | SK HOLDINGS CO LTD (KR) | 2010-08-18 | — | — | EP | disclosed |
| US-7678902-B2 | Process for the preparation of 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl)dibenzo[b,f][1,4]thiazepine | SK HOLDINGS CO., LTD. (KR) | 2010-03-16 | — | — | US | disclosed |
| US-20070225494-A1 | Process for the Preparation of 11-(4-[2-(2-Hydroxyethoxy)Ethyl]-I-Piperazinyl)Dibenzo[b,f][I,4]Thiazepine | SK CORPORATION (KR) | 2007-09-27 | — | — | US | disclosed |
| EP-1252151-B1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE AND INTERMEDIATES THEREFOR | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2004-03-17 | — | — | EP | disclosed |
| EP-1252151-A1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE AND INTERMEDIATES THEREFOR | EGIS GYOGYSZERGYAR RT. (HU) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001055125-A1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE AND INTERMEDIATES THEREFOR | EGIS Gyógyszergyár Rt. (HU) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225494-A1 | Process for the Preparation of 11-(4-[2-(2-Hydroxyethoxy)Ethyl]-I-Piperazinyl)Dibenzo[b,f][I,4]Thiazepine | TALDO1, QDPR, HDHD5 | DRD2 9/4885LMNA 3472/4885CHRM2 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.